The transcription factor AP-1 plays key roles in tumorigenesis, by regulating a variety of protein-coding genes, implicated in multiple hallmarks of cancer. Among non-coding genes, no AP-1 target has been described yet in tumorigenesis. MicroRNAs (miRNAs) are negative post-transcriptional regulators of protein-coding genes. miRNA expression signatures are highly relevant in cancer and several tumor-associated miRNAs (oncomirs) play critical roles in oncogenesis. Here, we show that the miRNA miR-21, which represents the most frequently upregulated oncomir in solid tumors, is induced by AP-1 in response to RAS. By analyzing validated miR-21 targets, we have found that the tumor suppressors PTEN and PDCD4 are downregulated by RAS in an AP-1-and miR-21-dependent fashion. We further show that, given the role of PDCD4 as negative regulator of AP-1, the miR-21-mediated downregulation of PDCD4 is essential for the maximal induction of AP-1 activity in response to RAS. Our data reveal a novel mechanism of positive autoregulation of the AP-1 complex in RAS transformation and disclose the function of oncomirs as critical targets and regulators of AP-1 in tumorigenesis.
Introduction
As a critical regulator of cell proliferation, apoptosis, tumor invasiveness and angiogenesis, the transcription factor AP-1, mainly formed by dimerization between members of the JUN and FOS protein families, is implicated in multiple hallmarks of cancer (Shaulian and Karin, 2002; Eferl and Wagner, 2003; Ozanne et al., 2007) . The tumorigenic role of AP-1, in response to multiple extra-nuclear oncoproteins, has been shown by both dominant-negative inhibitors (Olive et al., 1997; Young et al., 1999) and inactivation of individual AP-1 components. By gene knockout and knockdown analysis, it has been established that several AP-1 components, such as c-Jun, Fra-1 and Fra-2 act as oncoproteins, whereas others, such as JunB, JunD and c-Fos can also act as tumor suppressors, depending on the cell context and genetic background of the tumor. The cancer-associated changes of AP-1 composition and activity result from altered transcriptional and posttranscriptional regulation, along with post-translational modifications of the individual JUN and FOS family members (Eferl and Wagner, 2003) .
RAS oncogenes, mutationally activated in about onethird of human cancers, are well-characterized inducers of AP-1 activity and RAS-dependent AP-1 compositional changes have been described in various cell systems (Mechta et al., 1997; Vallone et al., 1997; Casalino et al., 2003) . During tumorigenesis, AP-1 regulates a wide variety of target genes, positively controlling cell proliferation, invasion and angiogenesis (Eferl and Wagner, 2003; Ozanne et al., 2007) On the other hand, cell cycle inhibitory and proapoptotic tumor suppressors, such as p16 INK4A and PTEN, are usually repressed by c-Jun/AP-1 (Bakiri et al., 2000; Hettinger et al., 2007; Vasudevan et al., 2007) . Although the AP-1-induced promoters are controlled by AP-1 binding to TRE elements, the genes inhibited by AP-1 do not share a common regulatory mechanism, thus suggesting the role of indirect control networks in AP-1-mediated gene repression.
MicroRNAs (miRNAs) are small non-coding RNAs of 20-24 nucleotides excised from B70 nt hairpin precursors (pre-miRNA), deriving from longer nuclear precursors (pri-miRNAs) transcribed by RNA polymerase II (Bartel, 2004; Cai et al., 2004) . Recently, the cell-and tissuespecific expression atlas of several hundreds of miRNAs, in multiple mammalian cell systems, has been compiled (Landgraf et al., 2007) . Usually, mature miRNAs repress the translation of their mRNA targets. In addition, miRNAs can destabilize their target transcripts, thus downregulating the expression of large fractions of cellular mRNAs (Lim et al., 2005) . Consequently, deregulation of one single miRNA is sufficient to trigger global alterations of genetic programs implicated in cell proliferation, differentiation, survival or invasiveness. The tumorigenic relevance of miRNAs is highlighted by the expression signatures inferred from miRNA expression profiling in a large variety of human cancers (Calin and Croce, 2006) . In addition to a broadly relevant signature including 21 miRNAs overexpressed in the majority of solid tumors (Volinia et al., 2006) , a variety of tumorspecific miRNA expression profiles are highly predictive for the diagnosis and prognosis of human malignancies, such as breast and lung cancer Yu et al., 2008) . Importantly, miRNAs exhibit high therapeutic potential, as shown by the in vivo application of chemically modified miRNA inhibitors (antagomirs), for treatment of animal models of human disease (Elmen et al., 2008) .
Several tumor-associated miRNAs exhibit oncogenic activity, whereas other miRNAs, downregulated in neoplastic cells, act as tumor suppressors (EsquelaKerscher and Slack, 2006) . The tumor-associated dysregulation of miRNAs can result from chromosomal rearrangements, such as the deletion abrogating the expression of the proapoptotic miR15/16 in B-CLL (Cimmino et al., 2005) . Alternatively, deregulated miRNA expression results from altered activity of oncogenic or tumor suppressor transcription factors, as for the c-Myc-mediated induction of the miR-17-92 miRNA cluster (O'Donnell et al., 2005) and the p53-mediated transactivation of the proapoptotic miR-34a (He et al., 2007) . A highly relevant tumor-associated miRNA is miR-21, which is overexpressed in almost all tumors analysed so far (Volinia et al., 2006) . The antiapoptotic role of miR-21, first described in glioblastoma (Chan et al., 2005) , has been further characterized in cholangiocarcinoma (Meng et al., 2006) and multiple myeloma cells (Loffler et al., 2007) . Moreover, miR-21 is implicated in breast cancer cell growth and invasiveness Zhu et al., 2008) , in agreement with its detection in a subset of miRNAs highly correlating with biopathologic features of breast cancer .
Here, we show that miR-21 is induced by AP-1 in response to the RAS oncoprotein, in a rat thyroid cell system. MiR-21 induction, which is necessary for thyroid cell viability, is mediated by the interaction of Fra-1 and Jun proteins with a regulatory region immediately upstream to the recently reported primiR-21 promoter (Fujita and Iba, 2008) . In addition, miR-21 mediates the RAS-dependent downregulation of two miR-21 targets, PTEN and PDCD4. The AP-1-induced miR-21 triggers the downregulation of PDCD4, which, in turn, is necessary for the maximal stimulation of AP-1 activity in response to the RAS oncoprotein. Our results, pointing to miR-21 as both target and regulator of AP-1, reveal a novel autoregulatory loop, mediated by miR-21 and PDCD4, in the control of AP-1 activity in RAS-transformed cells.
Results
Compositional change of the AP-1 complex in a RAS-inducible cell system To investigate the dynamics of AP-1 regulation in RAS transformation, we have utilized a RAS-inducible cell line (FRTL-5/ER-RAS), in which the tamoxifen-responsive estrogen receptor-H-RAS V12 fusion protein is stably expressed in FRTL-5 rat thyroid cells (De Vita et al., 2005) .
First, we characterized the expression of individual Jun and Fos family members during the time course of RAS stimulation (Figure 1 ). c-Jun was induced shortly after tamoxifen addition, starting to accumulate within the first hour and reaching a plateau in about 3 hours. JunB expression also peaked at 3 hours, but, differing from c-Jun, underwent a partial decline between 3 and 24 h, whereas JunD was well detectable in the absence of induction and did not exhibit significant variations during the 24 h time course. c-Fos was strongly induced within 1 hour, with a peak at 3 hours, followed by a sharp decline, between 3 and 6 h. The decline of c-Fos coincided with the onset of Fra-1 accumulation, which increased progressively from about 3 h, reaching a maximum within approximately 15 h. Fra-2 exhibited a biphasic pattern characterized by a small decline followed by an increase, although, after 24 h, Fra-2 level was slightly decreased with respect to the untreated control (Figure 1 ). These data suggest that while at 3 hours from RAS induction the AP-1 complex is predominantly formed by c-Jun and JunB along with A RAS-dependent AP-1-miR-21-PDCD4 regulatory loop F Talotta et al c-Fos, at 24 h AP-1 includes the Jun proteins, along with Fra-1 and a small amount of Fra-2. The interplay between c-Fos and Fra-1 suggests that, early after RAS activation, the transient induction of c-Fos is necessary for the subsequent self-sustained expression of Fra-1 (Casalino et al., 2003) , which appears to constitute the majority of AP-1 heterodimers, within 24 h from RAS induction. No further changes of AP-1 composition were observed after 24 h (data not shown). Figure 2a ). The analysis of several known AP-1 targets showed that the expression of the AP-1-autoregulated Fra-1 oncoprotein was totally abrogated by the dominant-negative inhibitor. In addition, the RAS induction of the cyclin D1 transcript was significantly blunted, whereas the MMP9 mRNA induction was fully abrogated by the AP-1 inhibitor (Figure 2b ). The drastic suppression of AP-1 activity was paralleled by a significant inhibition of the conditionally transformed phenotype. Although in parental cells RAS induction resulted in morphological transformation with the appearance of a large fraction of round and highly refractile cells within 3 days of tamoxifen treatment, the loss of epithelial morphology was almost completely prevented in the A-FOS-expressing cell line (Figure 2c) . Finally, the analysis of cell viability in the presence of tamoxifen showed a significantly decreased growth rate in the A-FOS cells, compared with the parental cell line (Figure 2d ).
AP-1 mediates the induction of miR-21 in response to the RAS oncoprotein
To identify the onco-miRNAs regulated by AP-1 in response to the RAS oncoprotein, we analysed the RASand AP-1-dependent expression of several members of the earlier reported miRNA signatures of papillary thyroid carcinoma (He et al., 2005; Pallante et al., 2006) , in the A-FOS, compared with the parental cell line (data not shown). QRT-PCR showed that miR-21 was induced by RAS, about fivefold in the FRTL-5/ER-RAS cell line, compared with less than twofold in the A-FOS cells (Figure 3a) . Then, we analysed the time course of miR-21 induction by primer extension. The mature miRNA became detectable between 12 and 24 h, reaching a maximum at 48 h, whereas no induction was observed in the A-FOS cells ( Figure 3b ). As primer extension did not allow visualizing the pre-miR-21, we performed Northern blotting. Hybridization with an LNA-probe showed that the rat 92-nt precursor was much less abundant than the 22-nt miR-21. The kinetics were comparable to the mature miRNA, which exhibited an intermediate expression at 24 h, reached a plateau within 48 h and remained constant over 1 week. No induction could be detected in the cell line expressing the dominant-negative AP-1 inhibitor ( Figure 3c ). Because of the discrepancy between the early induction of AP-1 components (c-Jun, JunB and c-Fos; Figure 1 ), and in vitro TRE-binding activity (not shown) compared with the delayed accumulation of pre-miR-21 and miR-21, we analysed the induction of the miR-21 primary transcript (pri-miR-21). Time course analysis (Figure 3d ) revealed that pri-miR-21 was already detectable at 3 hours, and did not increase further during a 24-h tamoxifen treatment. Therefore, the delayed accumulation of miR-21 results from the post-transcriptional processing of its RAS-induced primary transcript.
Fra-1 is recruited along with c-Jun and JunB on a conserved miR-21 5 0 -flanking region The results of Figure 3 showed that AP-1 activity was necessary for the RAS-dependent induction of miR-21. To test if miR-21 might represent a direct transcriptional target of AP-1, we investigated the association of AP-1 components with the miR-21 promoter region. The human miR-21 is processed from a 72-nt premiRNA deriving from a 4300-nt non-coding precursor (pri-miR-21), transcribed from a polII-dependent promoter, localized within an intron of the TMEM49 gene (Fujita and Iba, 2008 ).
First, we tested the c-Jun association with the rat primiR-21 5 0 -flanking region, inferred from the alignment with the human sequence, in chromatin from tamoxifeninduced ER-RAS cells. ChIP analysis, by using five amplicons spanning 4 kb across the pri-miR-21 start site (Figure 4a ), revealed the association of c-Jun with a 328-bp fragment. The acetylated histone H3 (Ac-H3) was detected on the same chromatin fragment, possibly reflecting the c-Jun-mediated recruitment of histoneacetyl-transferases. Interestingly, a downstream fragment, exhibiting a near-background recruitment of c-Jun, was highly enriched by Ac-H3-specific chromatin immunoprecipitation, followed by q-RT-PCR. (Figure 4b ). Having identified the c-Jun-interacting region of the miR-21 promoter, we investigated the RAS-induced recruitment of the AP-1 components highly expressed at 48 h from RAS induction. We detected the tamoxifen-induced chromatin recruitment of Fra-1 and JunB along with c-Jun, whereas JunD was already associated with the miR-21 5 0 -flanking region prior to RAS induction (Figure 4c) . Therefore, the AP-1 complex bound to the putative miR-21 regulatory region in the absence of RAS is likely represented by JunD dimers, possibly containing Fra-2, whereas following RAS induction the major chromatin-associated complex is represented by Fra-1 heterodimers containing the three Jun-family partners.
Bioinformatics search for potential AP-1 sites in the rat pri-miR-21 5 0 -flanking region showed three conserved AP-1-like sequences clustered within a 205-bp region, in addition to an upstream AP-1 sequence not exhibiting inter-species conservation. The three potential TREs are contained within the fragment strongly enriched by ChIP analysis, thus suggesting that the RAS-dependent induction of pri-miR-21 is mediated by the interaction of Fra-1-containing heterodimers with a region containing three potential AP-1 sites. The alignment among multiple mammalian species revealed striking sequence conservation across the AP-1-like sites, except for a 12-nucleotide insertion in the mouse and rat sequences (Supplementary Figure 1) .
Identification of the RAS-responsive AP-1 sites of the miR-21 promoter
To test the RAS and AP-1 responsiveness of the pri-miR-21 5 0 -flanking region, we cloned the abovecharacterized AP-1-interacting fragment upstream to a heterologous promoter driving a luciferase reporter. The construct harboring the candidate miR-21 enhancer was induced by tamoxifen, whereas coexpression with the dominant-negative GFP-A-FOS strongly decreased both basal activity and RAS induction (Figure 5a ). Quite recently, the human pri-miR-21 start site has been mapped , about 900 bp upstream to the earlier identified initiation site (Cai et al., 2004) , within a sequence region essentially identical between rat and human (Supplementary Figure 1) . To define the relative contribution of the individual AP-1 elements, we analysed several miR-21 promoter constructs, containing mutations in each of the three TREs . Although inactivating the two upstream sites minimally affected the tamoxifen-mediated RAS induction of the miR-21 promoter, the downstream AP-1 site exhibited the strongest effect, comparably with the triple mutation (Figure 5b ). A RAS-dependent AP-1-miR-21-PDCD4 regulatory loop F Talotta et al PDCD4 and PTEN are downregulated by an AP-1-and miR-21-dependent mechanism in response to RAS Several miR-21 target transcripts, including the tumor suppressors PDCD4 (Frankel et al., 2008; Asangani et al., 2008; Lu et al., 2008) , PTEN (Meng et al., 2007) and TPM1 have been experimentally validated.
The analysis of the RAS-and AP-1-dependent expression of PDCD4 and PTEN revealed that both proteins were inhibited by RAS induction, in the FRTL-5/ER-RAS cell line (Figure 6a ). PDCD4, represented by a doublet, likely reflecting distinct phosphorylation isoforms, was almost completely downregulated within 72 h of tamoxifen treatment, whereas PTEN exhibited a smaller fold decrease. The RAS-dependent downregulation of both proteins was fully abrogated in the absence of AP-1 activity, as shown from the analysis of the A-FOS cells. Unexpectedly, another earlier reported miR-21 target (TPM1) was induced, rather than downregulated, in response to RAS induction (Supplementary Figure 2) .
To understand if the PDCD4 and PTEN downregulation was mediated by miR-21, we inhibited miR-21 expression, by using a chemically modified miR-21 inhibitor (anti-miR-21 LNA; Frankel et al., 2008) . The miR-21 knockdown was monitored by using a construct containing the miR-21-complementary sequence downstream to a luciferase gene (Frankel et al., 2008) . The miR-21-dependent reporter activity was significantly downregulated in response to tamoxifen induction. The inhibition was totally relieved by the anti-miR-21 LNA, which increased also the uninduced level, likely reflecting the inhibition of the low amount of miR-21 expressed in uninduced cells (Figure 6b ). The specific inhibition of miR-21 was further confirmed by Northern hybridization, showing that miR-21 expression was completely suppressed by the transfected inhibitor, at all time points of tamoxifen induction (Figure 6c ). Immunoblotting analysis showed that, at 48 and 72 h, coinciding with the maximum accumulation of miR-21, the RAS-induced downregulation of PDCD4 was almost completely antagonized by the anti-miR-21 LNA, compared with the control cells treated with a scrambled LNA. Therefore, miR-21 is responsible for the downregulation of PDCD4 in response to the RAS oncoprotein. Differing from PDCD4, PTEN expression was only partially inhibited by RAS induction. Nevertheless, the partial downregulation of PTEN was abrogated by the antagomir-LNA, thus showing that also PTEN is targeted by miR-21, in the RAS-inducible thyroid system (Figure 6c ).
The miR-21-mediated downregulation of PDCD4 is required for full induction of AP-1 activity in response to RAS Earlier, it was reported that PDCD4 inhibits the AP-1 activity (Yang et al., 2003b; Wang et al., 2007) , likely by interfering with the JNK/c-Jun pathway (Bitomsky et al., 2004; Yang et al., 2006) . To test the PDCD4 inhibitory activity in FRTL-5/ER-RAS cells, we analysed the tamoxifen induction of a prototype AP-1 reporter, in presence of increasing amounts of the PDCD4 expression vector. We also analysed the PDCD4 inhibitory activity toward the ectopically expressed c-Jun/Fra-1-tethered heterodimer (Bakiri et al., 2002) . Cotransfection analysis showed that PDCD4 decreased significantly both the AP-1 activity induced by either the RAS oncoproteins (Figure 7a ) or the coexpressed c-Jun/Fra-1 heterodimer (Figure 7b ), which represents one of the major RASinduced AP-1 complexes.
Having shown that PDCD4 is downregulated by the RAS-induced miR-21 (Figure 6c ) and that PDCD4 A RAS-dependent AP-1-miR-21-PDCD4 regulatory loop F Talotta et al inhibits AP-1 (Figures 7a and b) , we postulated that miR-21 expression might be necessary to attain maximal AP-1 activation in response to the RAS oncoprotein. Therefore, we analysed the effect of miR-21 inhibition on the basal and RAS-induced AP-1 reporter activity. As in Figure 6c , miR-21 was inhibited by transfecting the anti-miR-21 LNA before tamoxifen induction. Although cotransfection with the control-scrambled LNA did not affect the RAS-induced activity of the AP-1 reporter, the anti-miR-21 LNA significantly blunted the tamoxifen induced without affecting the basal AP-1 activity in uninduced cells. To test if the decreased AP-1 induction was consequent to the increased PDCD4 expression resulting from the inhibition of miR-21, we assayed the AP-1 reporter activity in presence of the miR-21 inhibitor along with the PDCD4 siRNA. The results showed that the knockdown of PDCD4 strongly induced the AP-1 activity, as shown by A RAS-dependent AP-1-miR-21-PDCD4 regulatory loop F Talotta et al
show that miR-21 expression is necessary to achieve the maximal induction of AP-1 in response to RAS, by mediating the release of the PDCD4-dependent inhibition of AP-1 activity.
miR-21 positively controls thyroid cell viability in response to the RAS oncoprotein We investigated the role of miR-21 in the reversibly transformed phenotype of rat thyroid cells, by treating the FRTL-5/ER-RAS with the anti-miR-21 LNA. First, we found that the tamoxifen-induced changes of cell morphology ( Figure 2c) were not affected after transfecting the miR-21 inhibitor (data not shown). At variance, the proliferation rate was significantly decreased when the tamoxifen-induced FRTL-5/ER-RAS cells were treated with the anti-miR-21 LNA, compared with control cells transfected with a scrambled LNA (Figure 8a ). We postulated that the lack of miR-21 could be responsible, at least in part, for the compromised growth of the A-FOS-expressing cells (Figure 2d ). Therefore, we tested the effect of the ectopic expression of miR-21 in the AP-1-defective cell line, by transient transfection of the miR-21 precursor (pre-miR-21), as described (Frankel et al., 2008) . Cell viability was significantly increased in the A-FOS cells transiently overexpressing the pre-miR-21, compared with a control dsRNA (Figure 8b ). These results suggest that, by positively controlling thyroid cell viability, miR-21 is a determinant of the effect of AP-1 on the growth of FRTL-5 cells expressing the RAS oncoprotein.
Discussion
Recent reports show that tumor-associated miRNAs play key roles as targets of oncogenic or tumor suppressor transcription factors, such as c-Myc and p53 (O'Donnell et al., 2005; He et al., 2007) . Here, we identify the oncomir-21 as transcriptional target of the AP-1 complex in response to the RAS oncoprotein. The AP-1-induced miR-21 positively controls the growth of rat thyroid cells and downregulates the tumor suppressors PDCD4 and PTEN. The inhibition of PDCD4, in turn, contributes to the increase of AP-1 activity, thus revealing a novel AP-1 autoregulatory mechanism in RAS transformation. The RAS-dependent induction of miR-21 is characterized by an extended lag between the early increase of AP-1 activity and the delayed accumulation of miR-21. Such retardation results from the processing of the 4300-nt primary miR-21 transcript (pri-miR-21) into the 92-nt rat pre-miR-21 (Figure 3 ). Quite recently, it has been shown that maturation of the constitutively expressed primary precursor is the major mechanism of miR-21 regulation in response to TGF-b in both VSMCs and breast carcinoma cells (Davis et al., 2008) . Therefore, we are currently investigating the role of the TGF-b-SMAD pathway in the RAS-dependent regulation of miR-21 in thyroid carcinoma cells.
Biochemical analysis of the miR-21 5 0 -flanking sequence revealed a highly conserved region containing three AP-1 sites, to which Fra-1-containing heterodimers are recruited in response to RAS induction. Functional assays showed that the 3 0 AP-1 site is the major RAS-responsive element of the miR-21 promoter (Figures 4 and 5) .
Previously, two STAT3 sites, localized downstream to the AP-1 sites, have been implicated in the interleukin-6-mediated induction of miR-21, in multiple myeloma cells (Loffler et al., 2007) . Remarkably, the induction of interleukin-6 has been recently involved in the mechanisms of RAS-dependent tumorigenesis in vivo (Ancrile et al., 2007) . Although this paper was submitted for publication, a paper reporting the AP-1-dependent regulation of miR-21 has been published. In a human promyelocytic cell line, the phorbol ester induction of miR-21 is mediated by AP-1, in cooperation with the nuclear factor PU.1, which binds to the ETS sites adjacent to the AP-1 elements . These findings prompt to test the function of both STAT3 and ETS family factors in the RAS-dependent regulation of the miR-21 enhancer.
Among the many bioinformatically predicted miR-21 targets, four have been experimentally validated. They encode for tumor suppressor proteins, including the phosphatase PTEN in human hepatocellular carcinoma (Meng et al., 2007) , the cytoskeleton component tropomyosin-1 (TPM1) in breast cancer cells , the translational regulator PDCD4 in colorectal carcinoma and breast cancer cells (Asangani et al., 2008; Frankel et al., 2008; Zhu et al., 2008) , maspin in breast cancer cells (Zhu et al., 2008) . Moreover, in the recent report on the PMA-mediated induction of miR-21 in PML cells, the transcript encoding the nuclear factor NFI-B was characterized as a novel miR-21 target .
In our cell system, miR-21 mediates the AP-1-dependent downregulation of both PTEN and PDCD4, in response to the RAS oncoprotein ( Figure 6 ). Remarkably, PTEN has been described earlier as a negative regulatory target of AP-1. The proapoptotic expression of PTEN is inhibited by c-Jun, in both normal and RAS-transformed mouse fibroblasts. Accordingly, the PTEN and c-Jun levels inversely correlate in a panel of tumor cell lines. Although c-Jun was shown to inhibit the PTEN promoter, the PTEN 5 0 -flanking region targeted by c-Jun was not identified unambiguously (Hettinger et al., 2007; Vasudevan et al., 2007) . In our RAS-inducible cell system, transcriptional inhibition does not seem to play a major role in the downregulation of PTEN, as the effect of RAS is entirely relieved by the inhibition of miR-21 (Figure 7c ) affecting PTEN at the post-transcriptional level (Meng et al., 2007) .
For the first time to our knowledge, we show that the tumor suppressor PDCD4 is negatively controlled by RAS. As for PTEN, the RAS-dependent downregulation of PDCD4 is predominantly mediated by miR-21. It has been reported that PDCD4 expression is controlled by ubiquitylation and proteasomal degradation triggered by S6K1-phosphorylation, during cell cycle re-entry (Dorrello et al., 2006) . This rapid control mechanism is not implicated in the RAS-dependent downregulation of PDCD4, in which the decrease of PDCD4 parallels the slow induction of miR-21 (Figure 3) and is relieved by the miR-21 knockdown ( Figure 6 ).
Because of its ability to suppress neoplastic transformation both in vitro (Yang et al., 2003b) and in vivo (Jansen et al., 2005) , PDCD4 represents a critical target of miR-21 in oncogenesis. The downregulation of PDCD4 represents a major determinant of the effect of miR-21 on invasion and metastasis in colorectal and breast cancer, in which PDCD4 expression exhibits an Figure 3) .
A RAS-dependent AP-1-miR-21-PDCD4 regulatory loop F Talotta et al inverse correlation with miR-21 (Asangani et al., 2008; Zhu et al., 2008) . Interestingly, PDCD4 was characterized as a powerful inhibitor of AP-1 activity (Yang et al., 2003b; Wang et al., 2007) . In addition to being translationally repressed by miR-21 (Asangani et al., 2008; Frankel et al., 2008; Zhu et al., 2008) , PDCD4 itself is a translational repressor, inhibiting the translation initiation factor eIF4A (Yang et al., 2003a) . PDCD4 inhibits the activity of AP-1 and other transcription factors, including b-catenin/Tcf (Wang et al., 2007) and Sp1/Sp3 (Leupold et al., 2007) . PDCD4 affects AP-1 by indirect mechanisms, likely mediated by the decreased synthesis of MAP4K1, affecting the activity of the JNKK-JNKc-Jun pathway (Bitomsky et al., 2004; Yang et al., 2006) .
Our data suggest that the release of the PDCD4-mediated repression of AP-1 activity is crucial for the induction of AP-1 target genes in tumor progression. Further analysis will allow identifying the subsets of genes regulated by AP-1 in a miR-21-and PDCD4-dependent fashion. Interestingly, in hepatocellular carcinoma cells, prototype AP-1 target genes, like MMP-2 and MMP-9, are induced by miR-21 (Meng et al., 2007) , thus suggesting a role for the miR-21-PDCD4-AP-1 pathway in the control of neoplastic cell invasion. Given the AP-1-dependent regulation of the miR-21 promoter, miR-21 might boost its own transcription, through the miR-21-PDCD4-AP-1 pathway (Figure 9) . Interestingly, in the recent report on the PMAinduction of the miR-21 promoter, the transcript encoding for the transcription factor NFI-B was identified as an miR-21 target. As NFI-B is a transcriptional inhibitor of miR-21, the miR-21-mediated translational repression of NFI-B accelerates its clearance from the miR-21 promoter after PMA-induction . We speculate that PDCD4 and NFI-B might participate to parallel autoregulatory loops, sustaining the expression of miR-21 in physiological and pathological contexts. 
